NO20023953L - Pyridinylimidazoler - Google Patents
PyridinylimidazolerInfo
- Publication number
- NO20023953L NO20023953L NO20023953A NO20023953A NO20023953L NO 20023953 L NO20023953 L NO 20023953L NO 20023953 A NO20023953 A NO 20023953A NO 20023953 A NO20023953 A NO 20023953A NO 20023953 L NO20023953 L NO 20023953L
- Authority
- NO
- Norway
- Prior art keywords
- pyridinylimidazoler
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0004053A GB0004053D0 (en) | 2000-02-21 | 2000-02-21 | Compounds |
| GB0015902A GB0015902D0 (en) | 2000-06-28 | 2000-06-28 | Compounds |
| PCT/GB2001/000736 WO2001062756A1 (en) | 2000-02-21 | 2001-02-21 | Pyridinylimidazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20023953D0 NO20023953D0 (no) | 2002-08-20 |
| NO20023953L true NO20023953L (no) | 2002-10-21 |
Family
ID=26243690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023953A NO20023953L (no) | 2000-02-21 | 2002-08-20 | Pyridinylimidazoler |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030166633A1 (no) |
| EP (1) | EP1257543A1 (no) |
| JP (1) | JP2003524010A (no) |
| KR (1) | KR20020073597A (no) |
| CN (1) | CN1404478A (no) |
| AR (1) | AR029803A1 (no) |
| AU (2) | AU3391801A (no) |
| BR (1) | BR0108437A (no) |
| CA (1) | CA2401036A1 (no) |
| CO (1) | CO5271680A1 (no) |
| CZ (1) | CZ20022852A3 (no) |
| HU (1) | HUP0204514A3 (no) |
| IL (1) | IL151319A0 (no) |
| MX (1) | MXPA02008082A (no) |
| NO (1) | NO20023953L (no) |
| NZ (1) | NZ520753A (no) |
| PL (1) | PL357420A1 (no) |
| WO (1) | WO2001062756A1 (no) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002225730A1 (en) * | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
| GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| GB0127433D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| EP1506191A1 (en) * | 2002-05-15 | 2005-02-16 | Smithkline Beecham Corporation | Benzoxazine and benzoxazinone substituted triazoles |
| US20040146509A1 (en) * | 2002-07-25 | 2004-07-29 | Zhihe Li | Methods for improvement of lung function using TGF-beta inhibitors |
| EP1575506A4 (en) * | 2002-07-25 | 2008-04-23 | Scios Inc | METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| AU2003256003A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
| CA2497971A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
| EP1542995A1 (en) | 2002-09-18 | 2005-06-22 | Pfizer Products Inc. | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
| MXPA05002981A (es) | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf). |
| CA2496295C (en) | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| EP1723146A1 (en) * | 2004-03-01 | 2006-11-22 | Eli Lilly And Company | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms |
| RU2367661C2 (ru) * | 2004-03-05 | 2009-09-20 | Тайсо Фармасьютикал Ко., Лтд. | Производные тиазола |
| US20080319012A1 (en) * | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US20070275968A1 (en) * | 2004-09-07 | 2007-11-29 | Hitoshi Kurata | Substituted Biphenyl Derivative |
| CN101223161A (zh) * | 2005-06-24 | 2008-07-16 | 健亚生物科技公司 | 治疗病毒感染的杂芳基衍生物 |
| KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
| WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| CA2685540C (en) | 2007-08-03 | 2018-10-16 | Graham Michael Wynne | Drug combinations for the treatment of duchenne muscular dystrophy |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| WO2009115572A2 (en) * | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| TWI410425B (zh) | 2010-12-03 | 2013-10-01 | Lilly Co Eli | 唑并［５，４－ｂ］吡啶－５－基化合物 |
| AU2012281281B2 (en) | 2011-07-13 | 2017-06-01 | Tiumbio Co., Ltd | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| JP6006794B2 (ja) * | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| EP4234545A3 (en) | 2011-07-29 | 2023-09-06 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
| WO2013170068A2 (en) | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| CN104520422B (zh) | 2012-05-30 | 2019-08-23 | 康奈尔大学 | 由人羊水来源的细胞生成功能性的和持久的内皮细胞 |
| US9873739B2 (en) | 2012-08-01 | 2018-01-23 | Ikaika Therapeutics, Llc | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4) |
| CN105229144A (zh) | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | 通过组合的遗传工程和化学工程经由正向编程产生肝细胞 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| EP3888640B1 (en) | 2013-06-05 | 2025-09-17 | Reverse Bioengineering, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| ME03421B (me) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| US20170107486A1 (en) | 2014-04-21 | 2017-04-20 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| ES2713452T3 (es) | 2014-04-22 | 2019-05-21 | Univ Basel | Proceso de fabricación para derivados de triazina, pirimidina y piridina |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN108779435B (zh) | 2015-12-07 | 2022-05-03 | 再生疗法有限公司 | 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法 |
| EP3397634A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| WO2018132279A1 (en) * | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| GB201718285D0 (en) | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| BR112021011224A2 (pt) | 2018-12-11 | 2021-08-24 | Theravance Biopharma R&D Ip, Llc | Inibidores de alk5 |
| WO2020132647A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| SG11202107707UA (en) * | 2019-01-22 | 2021-08-30 | Bisichem Co Ltd | A fused ring heteroaryl compound as an alk4/5 inhibitor |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| US20210139477A1 (en) * | 2019-07-16 | 2021-05-13 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| KR20220104208A (ko) * | 2019-11-22 | 2022-07-26 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린 |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| AR122711A1 (es) * | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
| WO2022006340A1 (en) * | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| EP4182308B1 (en) | 2020-07-15 | 2024-09-04 | Chiesi Farmaceutici S.p.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| ES2982017T3 (es) | 2020-07-15 | 2024-10-14 | Chiesi Farm Spa | Derivados de pirido-oxazina como inhibidores de ALK5 |
| EP4182323B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine amino derivatives as alk5 inhibitors |
| EP4267584A1 (en) | 2020-12-23 | 2023-11-01 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| US20250011299A1 (en) | 2021-09-21 | 2025-01-09 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| CN114380823B (zh) * | 2022-01-26 | 2023-06-23 | 中国药科大学 | 咪唑-2-甲胺类衍生物及其医药用途 |
| EP4514802A1 (en) | 2022-04-27 | 2025-03-05 | Chiesi Farmaceutici S.p.A. | Imidazole derivatives as alk5 inhibitors |
| CN115466260B (zh) * | 2022-09-06 | 2023-10-13 | 延边大学 | 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用 |
| CN121712526A (zh) | 2023-06-13 | 2026-03-20 | 辛瑟斯治疗股份有限公司 | 抗cd5抗体及其用途 |
| CN116891472A (zh) * | 2023-07-13 | 2023-10-17 | 延边大学 | 一种含咪唑结构的酰胺类衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH561717A5 (no) * | 1971-05-10 | 1975-05-15 | Ciba Geigy Ag | |
| MX9300141A (es) * | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| WO1995003297A1 (en) * | 1993-07-21 | 1995-02-02 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
| JPH09124640A (ja) * | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | ピリジルイミダゾール化合物、製法および農園芸用殺菌剤 |
| AU8757098A (en) * | 1997-06-30 | 1999-02-10 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
-
2001
- 2001-02-20 CO CO01013429A patent/CO5271680A1/es not_active Application Discontinuation
- 2001-02-20 AR ARP010100755A patent/AR029803A1/es not_active Application Discontinuation
- 2001-02-21 EP EP01905954A patent/EP1257543A1/en active Pending
- 2001-02-21 CA CA002401036A patent/CA2401036A1/en not_active Abandoned
- 2001-02-21 HU HU0204514A patent/HUP0204514A3/hu unknown
- 2001-02-21 IL IL15131901A patent/IL151319A0/xx unknown
- 2001-02-21 NZ NZ520753A patent/NZ520753A/en unknown
- 2001-02-21 CN CN01805374A patent/CN1404478A/zh active Pending
- 2001-02-21 PL PL01357420A patent/PL357420A1/xx not_active Application Discontinuation
- 2001-02-21 KR KR1020027010853A patent/KR20020073597A/ko not_active Withdrawn
- 2001-02-21 AU AU3391801A patent/AU3391801A/xx active Pending
- 2001-02-21 BR BR0108437-2A patent/BR0108437A/pt not_active IP Right Cessation
- 2001-02-21 JP JP2001562538A patent/JP2003524010A/ja active Pending
- 2001-02-21 WO PCT/GB2001/000736 patent/WO2001062756A1/en not_active Ceased
- 2001-02-21 AU AU2001233918A patent/AU2001233918B2/en not_active Ceased
- 2001-02-21 MX MXPA02008082A patent/MXPA02008082A/es unknown
- 2001-02-21 CZ CZ20022852A patent/CZ20022852A3/cs unknown
- 2001-02-21 US US10/204,370 patent/US20030166633A1/en not_active Abandoned
-
2002
- 2002-08-20 NO NO20023953A patent/NO20023953L/no not_active Application Discontinuation
-
2004
- 2004-01-29 US US10/767,943 patent/US20040220230A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001233918B2 (en) | 2004-06-24 |
| BR0108437A (pt) | 2005-06-28 |
| CO5271680A1 (es) | 2003-04-30 |
| PL357420A1 (en) | 2004-07-26 |
| HUP0204514A2 (en) | 2003-05-28 |
| CN1404478A (zh) | 2003-03-19 |
| CA2401036A1 (en) | 2001-08-30 |
| AR029803A1 (es) | 2003-07-16 |
| WO2001062756A1 (en) | 2001-08-30 |
| HUP0204514A3 (en) | 2004-07-28 |
| AU3391801A (en) | 2001-09-03 |
| NZ520753A (en) | 2004-08-27 |
| US20030166633A1 (en) | 2003-09-04 |
| MXPA02008082A (es) | 2003-02-27 |
| KR20020073597A (ko) | 2002-09-27 |
| NO20023953D0 (no) | 2002-08-20 |
| EP1257543A1 (en) | 2002-11-20 |
| CZ20022852A3 (cs) | 2003-04-16 |
| IL151319A0 (en) | 2003-04-10 |
| US20040220230A1 (en) | 2004-11-04 |
| JP2003524010A (ja) | 2003-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE290000T1 (de) | Muscarinagonisten | |
| ATE252099T1 (de) | Biarylcarboxamide | |
| NO20023953L (no) | Pyridinylimidazoler | |
| DE10136334B8 (de) | Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser | |
| ATE312098T1 (de) | Thiazinoxazolidinon | |
| ATA2932001A (de) | Schneefräse | |
| DE50108963D1 (de) | Schlauchklemme | |
| DE50106867D1 (de) | Kugelgelenk | |
| DE50108226D1 (de) | Vordralldüsenträger | |
| DE50102988D1 (de) | Bodenwischer | |
| DE50104056D1 (de) | Gewichtsmanschette | |
| DE50100710D1 (de) | Wischblatt | |
| ATE262530T1 (de) | Indolochinazolinone | |
| DE50104651D1 (de) | Fahrzeugfaltverdeck | |
| DE10192638T1 (de) | Bohrstangenladevorrichtung | |
| ATE509008T1 (de) | Sulfonylguanidine | |
| DE10196064T1 (de) | Halbleiterfotodektionsgerät | |
| DE50100817D1 (de) | Kugelgelenk | |
| DE50011511D1 (de) | Blowby-Heizung | |
| AR027931A1 (es) | Antitranspirantes | |
| DE10052925B4 (de) | Schaukelbett | |
| ATE476423T1 (de) | Benzoylpyridazine | |
| DE50007634D1 (de) | Kardioplegieballonkatheter | |
| DE10195909T1 (de) | Viehfüttervorrichtung | |
| AR027982A1 (es) | Aril- y heteroarilsulfonatos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |